BiovaxID® Personalized Lymphoma Vaccine is Featured in Article Published in HemOnc Today

TAMPA, Fla. & MINNEAPOLIS--(BUSINESS WIRE)-- Biovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today announced that an article was published in HemOnc Today, reporting on the promise of Biovest’s BiovaxID® personalized cancer vaccine for the treatment of non-Hodgkin’s lymphoma, an incurable form of blood cancer.

The article, titled, “Follicular Lymphoma Vaccine Specifically Targets Tumor Cells, Offers Individualized Treatment”, includes an interview with Biovest’s clinical consultant, Larry W. Kwak, M.D., Ph.D., Chairman of the Department of Lymphoma/Myeloma, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center (Houston, TX).

According to the article, “This vaccine (BiovaxID) opens new doors because, as great a drug as rituximab is, even in combination with chemotherapy, it does not cure patients with follicular lymphoma,” Dr. Kwak said. “The ultimate goal of curing patients is still an unmet need. This vaccine, in combination with chemotherapy and rituximab, has the potential to achieve that goal of curing patients.” Dr. Kwak was named to TIME Magazine’s “Top 100 – Most Influential People in the World” list in 2010 for his work on BiovaxID.

The complete HemOnc Today article can be accessed in the Media Center at Biovest's corporate website at: http://www.biovest.com/investor-relations/media-center

About BiovaxID®

Biovest's lead drug product is BiovaxID®, an autologous active immunotherapy (personalized cancer vaccine) for the treatment of certain B-cell subtypes of non-Hodgkin's lymphoma, an incurable form of blood cancer. Over the past decade, two Phase II clinical trials and a Phase III clinical trial have demonstrated strong and cumulative evidence with regards to BiovaxID vaccination’s safety and efficacy. With regards to safety, all clinical trials to date demonstrate that BiovaxID vaccination is highly safe and poses a nearly vanishingly small toxicity risk relative to approved anti-lymphoma agents. Moreover, BiovaxID provides substantial and durable clinical efficacy with the Phase III clinical trial demonstrating that BiovaxID significantly improves disease-free survival in follicular lymphoma and the Phase II mantle cell lymphoma clinical trial demonstrating that BiovaxID induces strong idiotype-specific T-cell responses which strongly correlate with highly-statistically significant overall survival.

About Biovest International, Inc.

Biovest International, Inc. is an emerging leader in the field of active personalized immunotherapies. In collaboration with the National Cancer Institute, Biovest has developed a patient-specific, cancer vaccine, BiovaxID®, with three clinical trials completed, including a Phase III study, demonstrating evidence of safety and efficacy for the treatment of indolent follicular non-Hodgkin’s lymphoma.

Headquartered in Tampa, Florida with its bio-manufacturing facility based in Minneapolis, Minnesota, Biovest is publicly-traded on the OTCQB™ Market with the stock-ticker symbol “BVTI”, and is a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: “ABPI”).

For further information, please visit: http://www.biovest.com

Forward-Looking Statements:

Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to statements about BiovaxID®, AutovaxID®, events occurring after dates hereof, and any other statements relating to products, product candidates, product development programs, the FDA or clinical study process including the commencement, process, or completion of clinical trials or the regulatory process. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions, and other statements identified by words such as "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Biovest to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Biovest undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. The product names used in this statement are for identification purposes only. All trademarks and registered trademarks are the property of their respective owners.



CONTACT:

Biovest International, Inc.
Corporate Contact:
Douglas Calder, 813-864-2558
Vice President, Strategic Planning & Capital Markets
[email protected]

KEYWORDS:   United States  North America  Florida  Minnesota

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

A suspected cancer-causing impurity that has been found in some blood pressure medicines has now shown up in Zantac and some OTC antacids.

Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.

New data shows a significant reduction in relapse rates in patients taking Novartis' repurposed cancer drug ofatumumab.